At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 328 enrolled
Drug / intervention
Aliskiren +1 moredrug
Likely dose
Aliskiren 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.
In Brief
A Phase 4 clinical trial evaluating Aliskiren and Placebo to Aliskiren for Essential Hypertension. Completed, enrolled 328 participants across 3 sites in 3 countries.
Detailed Summary
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesGermany, Spain, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedApr 2008
Primary CompletionNov 2008
TodayJul 2026
First PostedApr 9, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.2 years ago
Interventions
Aliskirendrug
Aliskiren supplied in 150 mg and 300 mg tablets.
Placebo to Aliskirendrug
Placebo to Aliskiren matching 150 and 300 mg tablets